Introduction
Multiple myeloma (MM) is a B-cell malignancy characterized by multifocal accumulation of monoclonal plasma cells in the bone marrow. It represents B10% of hematological malignancies, with B4 new cases/100 000 of the general population per year. 1 Despite significant advances in recent therapy, including the use of newer therapeutic compounds such as thalidomide or bortezomib, which achieve remission in most patients, the majority of cases relapse and MM remains a lethal disease. 2 Clearly, new treatment strategies are required, and attention has focused on including immunotherapy in the setting of residual disease to attack tumor cells and clear disease. Immunotherapy encompasses diverse principles of manipulating host immunity against cancer, including active vaccination to generate cytotoxic T-lymphocytes (CTLs). As MM cells express major histocompatibility complex (MHC) class I molecules, inducing CD8
þ CTLs that recognize tumor-associated antigens may prove important. In MM, however, as in other tumors, it then becomes relevant to demonstrate that malignant cells actually process and present sufficient antigen-derived peptides to enable CTL recognition and killing, as there may be tumor orchestrated deficiencies in these pathways.
As a vaccination strategy, DNA fusion gene vaccines offer several advantages. By fusing a bacterial alert gene, encoding fragment C (FrC) of clostridial tetanus toxin, to a tumor antigen it has been shown that a striking potency is achieved, able to mount specific immune responses against antigen in several tumor models. [3] [4] [5] In MM, this vaccine design coupling FrC with tumor idiotype encoding genes provided protection against tumor challenge in the 5T33 murine myeloma model. 5 This has led to a phase I/II clinical trial of DNA vaccines targeting idiotype in MM, with vaccines generated specifically for each patient (Ottensmeier C et al., unpublished data). Fine tuning of the DNA vaccine design fusing a single domain (DOM) of FrC to a defined MHC class I epitope subsequently provided a means of generating effective CD8 þ T-cell responses to the epitope, even in a tolerized setting. [6] [7] [8] Importantly, this pDOM-epitope DNA vaccine design has now entered clinical use in our institution, and when coupled with electroporation (EP) boost, enhances vaccine-specific antibody responses. 9 To by-pass the constraints of generating individual vaccines, we have looked to develop a generic approach based on additional tumor-associated targets. Among these, the cancer testis antigens (CTAs), found to be expressed in several malignancies including MM, appear of particular interest. [10] [11] [12] CT genes display a pattern of normal expression in humans that can be restricted exclusively to germ line cells in testis. The fact that testis constitutes an immune-privileged site makes some CTAs essentially tumor-specific. 13, 14 As intracellular antigens, CTAs are processed and epitopes presented via HLA class I molecules.
Earlier studies in MM had suggested that CTA expression is largely restricted to late stage disease, but recent data indicates that many CTAs are expressed at disease presentation, and can also be seen in monoclonal gammopathy of undetermined significance, a benign plasma cell proliferation now thought to precede all MM. 15 By using an in silico-based search to identify putative CT genes on chromosome Xq28, we recently reported that a new CTA, PASD1 (PAS domain containing 1 gene) is also expressed in MM both at the transcript and protein levels. 16 We observed that PASD1 transcripts were frequently expressed in MM at a frequency greater than reported for NY-ESO-1, an antigen which has been actively targeted with immunotherapy in human MM.
16 PASD1 expression was first described in diffuse large B-cell lymphoma, with normal expression shown to be restricted to testis. 17 In MM, and in other tumor settings, 18 PASD1 appears to be an important generic tumor-specific antigen.
We report our findings using DNA fusion gene vaccine designs to target PASD1. To accelerate a potential clinical application, and as the HLA-A2 allele is the most prevalent class I molecule, we carried out these studies in an A2 transgenic model using HLA-A2 (HHD) mice that generate only HLA-A*0201-restricted CTL responses. 19 
Materials and methods

Cell lines
RMA-HHD cells (mouse lymphoma cell line stably transfected with HHD, kindly provided by Dr Lemonnier FA, Institut Pasteur, Paris, France), KMS-12-BM cells and MOLP-8 cells (both HLA-A*0201 negative human myeloma cell lines) and YAC-1 cells (mouse lymphoma cell line sensitive to natural killer cells cytotoxic activity) were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (Invitrogen Life Technologies, Paisley, UK). The Phoenix Amphotropic retroviral packaging cell line, kindly provided by Dr P Stevenson (Cambridge University, Cambridge, UK), was cultured in DMEM media (Lonza, Verviers, Belgium), supplemented with 10% heat-inactivated fetal calf serum, 1 mM sodium pyruvate, 2 mM L-glutamine, nonessential amino acids (1% of 100 Â stock; Invitrogen Life Technologies). Supernatant from the Phoenix Amphotropic packaging cells transiently transfected with the retroviral vector p.HHDmscvpuro (kindly provided by Dr Gisella Vittes, Cancer Sciences Division, University of Southampton School of Medicine, UK) was used to transduce the KMS-12-BM and MOLP-8 cell lines to create KMS-12-HHD and MOLP-8-HHD. The retroviral transfection followed the protocol from Dr G Nolan's laboratory (Stanford, USA), available online (http://www.stanford.edu/group/nolan/ protocols/pro_helper_dep.html). The Thiel (MM-derived) and Jurkat (T-cell leukemia-derived) cell lines were obtained as previously described. 18 
Western blot analysis
Western blotting for PASD1 protein detection was performed as previously reported. 18 Briefly, cell lysates were resolved by SDS-PAGE and transferred to Immobilon membranes (Millipore, Watford, UK). The membranes were then probed with the monoclonal antibody PASD1-2 (diluted 1:2), washed, incubated with horseradish peroxidase goat anti-mouse IgG (diluted 1:2000, Dakocytomation, Glostrup, Denmark), washed and the antigen/ antibody complexes visualized using the ECL chemiluminescent substrate (Amersham Biosciences, Buckinghamshire, UK).
Immunoperoxidase labeling
Cytocentrifuge preparations of the KMS-12-BM and MOLP-8 cell lines were fixed in acetone for 10 min at room temperature. After air-drying for 30 min the cells were then subjected to an indirect immunoperoxidase labeling procedure as previously described. 18 Briefly, the cells were incubated with the monoclonal antibodies PASD1-1 or PASD1-2, washed, incubated with horseradish peroxidase goat anti-mouse Ig (Dakocytomation) and the antigen:antibody complexes visualized using the Envision substrate (Dakocytomation), counterstained with haematoxylin and mounted in Apathys.
Peptides
The two HLA-A*0201 restricted epitopes, PASD1(1) (QLLDGFMITL) and PASD1(2) (YLVGNVCIL), previously identified in diffuse large B-cell lymphoma patients and reported by Ait-Tahar et al., 20 and the HLA class II-restricted p30 (FrC-derived: FNNFTVSFWLRVPKVSASHLE) peptide were synthesized commercially and supplied at more than 95% purity (PPR Ltd, Fareham, UK). To avoid disulfide bond formation because of the presence of cysteine, the PASD1(2) peptide was always used in presence of 200 mM Bond-Breaker TCEP solution (Pierce, Northumberland, UK).
Construction of DNA vaccines
Three vaccines were constructed, as previously described. 8 They encode the first domain of FrC (DOM), which contains the p30 T H epitope, fused to a sequence encoding PASD1(1) (p.DOM-PASD1(1)), PASD1(2) (p.DOM-PASD1(2)) peptides, or PASD1 full-length (p.DOM-PASD1FL; Figure 1 ). p.DOM-PASD1(1) and p.DOM-PASD1(2) were obtained by PCR using p.DOM as template, and PASD1FL was obtained by PCR using the clone PASD1v1 as template (primer sequences are available on request). After insertion in pcDNA3 (Invitrogen Life Technologies), construct integrity was confirmed by DNA sequencing and the expression and product size checked by in vitro transcription and translation using the TNT T7 coupled reticulocyte lysate system (Promega, Southampton, UK).
HLA-A*0201 transgenic mice HHD mice express a transgenic chimeric monochain MHC class I molecule, in which the COOH-terminus of human b2-microglobulin is covalently linked to the NH2-terminus of chimeric HLA-A2 a1 and a2 domains fused with the murine H-2D b a3 domain. 19 These mice lack cell-surface expression of mouse endogenous H-2 b class I molecules because of targeted disruption of the H-2D b and mouse b2-microglobulin genes.
Vaccination protocol
At 6-10-week-old HHD mice were injected intramuscularly in both quadricepses with a total of 50 mg of DNA in 100 ml saline on day 0. When indicated mice received booster injections with the same DNA vaccine coupled with EP on day 28 as described previously. 21 Animal experimentation was conducted within local 
Interferon-g (IFN-g) ELISpot
Vaccine-specific IFN-g secretion by lymphocytes from individual vaccinated mice was assessed ex vivo by ELISpot (BD Biosciences, San Diego, CA, USA) on day 14 or 36, as described previously. 6 Splenocytes were incubated with the HLAA*0201-restricted PASD1(1) peptide, or PASD1(2) peptide for 22 h to assess CD8 þ T-cell responses; the p30 peptide (derived from FrC fusion domain) was used to assess CD4 þ T-cell responses. Samples were tested in triplicates with a range of peptide concentrations; control samples were incubated without peptide or with an irrelevant HLA-A2-binding peptide. Data are expressed as the frequency of spot-forming cells (SFCs) per million lymphocytes. Responses were considered significant if the frequency of IFN-g-secreting cells was more than double the frequency detected in wells without peptide.
Cytotoxic T-cell expansion and detection
To assess specific CTL responses, vaccinated mice were killed at day 14 or 36 to harvest spleens. Single-cell suspensions were made from individual spleens. Splenocytes were washed and resuspended in 10-15 ml complete medium in upright 25-cm 2 flasks together with recombinant human interleukin-2 (20 IU/ml; Perkin-Elmer, Foster City, CA, USA) and peptide (0.1 mM). After 6 days of stimulation in vitro, cytolytic activity of the T-cell cultures was assessed by standard 5-h 51 Cr-release assay, as previously described. 6 Target cells (RMA-HHD, KMS-12-HHD, MOLP-8-HHD and YAC-1) were 51 chromium labeled during incubation with or without peptide, as indicated. Specific lysis was calculated by the standard formula (release by CTL-release by targets alone)/(release by 4% NP40-release by targets alone) Â 100%.
Results
p. DOM-PASD1(1) and p.DOM-PASD1(2) induce T-cell responses in HHD mice
A single priming dose of p.DOM-PASD1(1) or p.DOM-PASD1(2) DNA vaccine induced significant peptide-specific T-cell responses at day 14 as measured by ex vivo IFN-g production in 100 and 57% of the vaccinated HHD mice, respectively (Figure 2a ). The level of epitope specific T-cell response was 4twofold higher in mice vaccinated with p.DOM-PASD1(1) (median 117 SFCs/10 6 cells; 1 mM peptide) than in those vaccinated with p.DOM-PASD1(2) (median 53 SFCs/10 6 cells; 1 mM). The p.DOM control vaccine gave no PASD1(1) or PASD1(2) specific T-cell response (Figure 2a Cr-release assays. After expansion during 6 days with relevant peptide, CTLs from mice vaccinated with p.DOM-PASD1(1) or p.DOM-PASD1(2) were able to specifically lyse RMA-HHD cells loaded with relevant peptide (Figures 2b and c) . With p.DOM-PASD1(1), CTLs were induced in 4/4 mice (8/8 when pooling both experiments) with 40-70% of target cell killing at the highest E:T ratio (Figure 2b) . With p.DOM-PASD1(2), CTLs showed a cytolytic activity in 3/4 vaccinated mice. Similarly to p.DOM-PASD1(1), this cytolytic activity was PASD1(2) peptide specific with 40-90% of peptideloaded target cells lysed (Figure 2c ). CTLs from mice vaccinated with the control vaccine p.DOM and restimulated with the peptide of interest before the CTL assay did not show any killing of peptide-loaded target cells (Figures 2b and c) . The target cell lysis was peptide specific as no killing of RMA-HHD cells, alone or loaded with an irrelevant peptide was observed. YAC-1 cells were also used as target control cells to show that the cytolytic activity was not due to natural killer cell activity (Figures 2b  and c) . Thus, the cytolytic activity observed after vaccination was peptide specific.
DNA vaccination with EP improves specific T-cell responses
DNA vaccination with EP in a homologous prime/boost strategy generates superior T-cell responses. 21 To see if boosting with p.DOM-PASD1 epitope DNA vaccines would generate superior specific immune responses, HHD mice received a booster injection followed immediately by EP at day 28. Their spleens were harvested 8 days later to assess the T-cell responses induced. After prime/boost vaccination with p.DOM-PASD1(1), the p30 specific T-cell response was similar to the one observed after priming, but the PASD1(1) specific T-cell response increased from 117 SFCs/10 6 splenocytes after priming to 275 SFCs/10 6 splenocytes after prime/boost which represents 4twofold increase in the T-cell response (Figure 3a, left panel) . For the cytolytic activity of the induced T-cells, we observed an augmentation in specific target cell killing with the highest E:T ratio (Figure 3b) . Hence, the prime and boost strategy increased the frequency of induced CTLs with a specific cytolytic ability. With regard to p.DOM-PASD1(2), although the frequency of responding mice was increased after boosting with p.DOM-PASD1(2), there was no improvement in the frequency of the specific CD8 þ T cells induced (data not shown). endogenously. Therefore, we used the KMS-12-BM and MOLP-8 cell lines in which PASD1 expression, previously reported for KMS-12-BM at the mRNA level 16 was verified at the protein level by immunohistochemistry using two specific monoclonal antibodies, demonstrating labeling of 495% cell nuclei (Figure 4a ). Western blotting with the PASD1-2 monoclonal antibody confirmed the presence of a protein exhibiting a molecular weight consistent with that of the full-length PASD1b protein in these cells (PASD1-2 Figure 4b ). This predicts that both PASD1(1) and PASD1(2) epitopes are present in the endogenous protein in KMS-12-BM and MOLP-8 cells. An additional higher molecular weight protein band was also observed when labeled with the PASD1-2 antibody (which specifically recognizes the unique C-terminus of the PASD1b protein; Figure 4b ), suggesting the presence of additional PASD1 isoforms. Targets were generated by transducing KMS-12-BM and MOLP-8 with the chimeric HHD MHC molecule to enable antigen recognition by HLA-A2-restricted CTLs induced in humanized HHD transgenic mice.
Vaccination of mice with p.DOM-PASD1(1) generated CTLs which mediated a specific lysis of 73% (median, range 23-80%) KMS-12-HHD cells and 49% (34-70%) MOLP-8-HHD cells when loaded with PASD1(1) peptide (Figures 5a and b) , which was consistent with the results obtained with peptide-loaded RMA-HHD cells (Figure 2 ). More importantly, the PASD1(1) specific CTLs induced by the vaccine were able to lyse 31% (14-40%) of the KMS-12-HHD cells (Figure 5a ) and 11% (9-28%) of the MOLP-8-HHD cells (Figure 5b ) without peptide loading. This was peptide specific as we obtained the same result when the KMS-12-HHD cells were loaded with an irrelevant peptide (data not shown). Thus, the PASD1(1) epitope is naturally processed and presented in the human MM cell lines KMS-12-HHD and MOLP-8-HHD at a level permitting a significant level of killing.
CTLs from mice vaccinated with p.DOM-PASD1(2) were able to specifically lyse 67% (38-82%) KMS-12-HHD cells (Figure 5a ) and 24% (11-30%) MOLP-8-HHD cells (Figure 5b ) when loaded with PASD1(2) peptide. However, the same cell lines by themselves were not lysed by the p.DOM-PASD1 (2) induced CTLs. These data show that the PASD1(2) epitope is not naturally processed and presented by these MM cell lines at a level that allows recognition and lysis by the p.DOM-PASD1 (2) induced CTLs.
Full-length PASD1-encoding vaccine (p.DOM-PASD1FL) induces PASD1(1) specific T-cell responses in HHD mice
We aimed to examine which epitopes are processed and presented when full-length PASD1 antigen is delivered by vaccination in this model. HHD mice were vaccinated with p.DOM-PASD1FL and their spleens were harvested 14 days later to assess the PASD1(1) and PASD1(2) specific T-cell responses induced. As shown in Figure 6a , all vaccinated mice gave a p30 specific T-cell response to the DOM component of the vaccine, validating vaccine immunogenicity. A PASD1(1) specific T-cell response was observed in 8/8 mice with a median of 756 SFCs/10 6 splenocytes ( Figure 6a ). As for PASD1(2), only 1/8 mice showed a specific T-cell response, but this was lower (205 SFCs/10 6 splenocytes) than observed for PASD1(1). However, in 1/8 mice both PASD1(1) and PASD1(2) epitopes CTLs from the p.DOM-PASD1FL vaccinated mice were restimulated with either PASD1(1) or PASD1(2) peptides before assessing their cytolytic activity toward KMS-12-HHD and MOLP-8-HHD target cells. With PASD1(1) peptide, CTLs were able to lyse KMS-12-HHD cells loaded with the peptide (67% of specific lysis at the highest E:T ratio), and notably, KMS-12-HHD cells without peptide (35% of specific lysis at the highest E:T ratio; Figure 6b ), which is equivalent to what we have observed with p.DOM-PASD1(1) (Figure 5a) . Similarly, CTLs stimulated with PASD1(1) lysed 23% (11-40%) of target MOLP-8-HHD cells without peptide loading (Figure 6c) . In marked contrast, the PASD1(2) restimulated CTL cultures generated by p.DOM-PASD1FL did not show any cytolytic activity against target cells from the two cell lines (Figures 6b and c) .
Discussion
This study evaluated PASD1 as a target for DNA fusion gene vaccines in MM. We had previously shown that PASD1 expression persists post-therapy, 16 suggesting that its retention may be associated with the 'feeder' or 'stem' cell in MM at relapse, and likely to be relevant to tumor progression. It also indicates that vaccination during minimal residual disease to generate anti-PASD1 immunity appears to be relevant.
The intraclonal pattern of PASD1 transcript expression in our previous study was found restricted to 27-40% of MM tumor cells. 16 This level of PASD1 expression in MM cells appeared comparable to, or exceeded that of NY-ESO-1, an important CTA in MM reported in B25% of tumor cells. 22 At the single Targeting multiple myeloma by DNA vaccination D Joseph-Pietras et al cell level, PASD1 transcripts were also detected in B40% of the KMS-12-BM cells that were generated as vaccine targets (data not shown). However, at the protein level PASD1 was detectable in 495% in virtually all cells, indicating an underestimation of antigen frequency at the transcript level, and reinforcing the relevance of PASD1 as a target for immunotherapy in MM. PASD1 is a neoantigen in HHD mice, although a murine ortholog exists. 17 As such, it appears to mimic expression of CTAs in human tumors, which are re-expressed in malignant adult somatic cells virtually as neoantigens, thereby excluding potential tolerogenic mechanisms associated with self-antigens. We examined and compared two PASD1-derived HLA-A2-restricted class I epitopes, both previously shown to be recognized by human CD8 þ T cells in A2-positive diffuse large B-cell lymphoma patients, 20 when presented as single epitopes via DNA vaccines or as components of the full-length antigen to evaluate endogenous processing and presentation.
Of the two epitopes, the PASD1(1) specific vaccine generated a robust T-cell response that was twofold greater than induced by PASD1(2) vaccine following a single priming dose. Although T cells induced with both vaccines were cytolytic to the same level against RMA-HHD target cells when loaded with relevant antigen at the same peptide concentration, PASD1(1)-CTLs were more consistently induced. This indicates that a level of T cells induced by PASD1 epitopes is sufficient to lyse RMA-HHD cells. Notably, both epitopes are efficiently presented by endogenous antigen processing cells when delivered as a fusion protein via DNA vaccines, which function mainly by cross-presentation. 23 PASD1 epitopes in this format share the exact preceding flanking region in the DOM region of FrC, which will govern trimming to release peptide. These data also indicate that an A2-restricted T-cell repertoire is available to recognize both PASD1-derived epitopes in the HHD mouse. Delivery of vaccines by EP augmented the frequency of PASD1(1) specific induced CTLs, but had no significant effect on the PASD1(2) specific induced CTLs, revealing PASD1(2) as a weakly immunogenic epitope as compared with PASD1(1).
However, when attention turned to evaluating human MM expressing chimeric HHD class I molecules, by using the KMS-12-HHD and MOLP-8-HHD cell lines, differences emerged in relation to these two PASD1 epitopes. While both epitope-specific DNA vaccines generated CTLs, and were able to lyse chimeric MM cells when loaded with relevant peptide, only PASD1(1) CTLs were able to kill these cells in the absence of exogenous peptide, indicating that this peptide is naturally processed and presented at a sufficient pMHC density to allow direct killing.
This observation was more pronounced when we examined the efficacy of the DNA vaccine encoding full-length PASD1 antigen. With p.DOM-PASD1FL, a single priming dose invariably elicited high levels of PASD1(1)-specific T cells, but failed to induce responses to PASD1(2) in all but one animal. Of these, only PASD1(1) T cells were cytolytic against the highly relevant chimeric MM cells both when loaded with this peptide, and importantly, against KMS-12-HHD and MOLP-8-HHD cells without peptide. In the latter cases, 25-35% specific lysis was observed at the highest E:T ratio. In contrast, cultures derived from vaccinated mice with added PASD1(2) were ineffective in lysis of MM target cells. These data confirm that full-length PASD1 is taken up by antigen presenting cells, and that of the two epitopes examined, only PASD1(1) is presented from PASD1 at a level sufficient for CTL activation and CTL-mediated tumor cell killing. This fits the expected scenario of epitope dominance within any given tumor antigen. 24 The precise hierarchy of dominance will require further studies in human MM, using homologous CTLs and targets. This arises from observations from the Oxford group (KAT, AHB, KP) that anti-PASD1(2) T cells generated in A2-restricted diffuse large B-cell lymphoma patients were also able to lyse another MM cell line (Thiel) without peptide loading. 20 Nevertheless, these data reveal that human MM cells retain an intact MHC class I processing and presentation machinery able to present CTL epitopes at a relevant density, as exemplified by PASD1(1) in the present study.
Our findings suggest that CTAs are suitable targets to ablate MM tumor cells via DNA fusion gene vaccines. However, CTAs as targets require important additional considerations for vaccination strategies. This follows from the intraclonal nature of CTA expression in MM, for example, NY-ESO-1. 16, 22 Importantly, PASD1 expression at the protein level as shown here may bypass this constraint. Nevertheless, the large repertoire of CTAs now identified in MM, including at presentation disease, suggest optimism as a minimal number of different CTAs should be identifiable to target all tumor cells within a monoclonal expansion, thereby necessitating a multivaccine strategy. These studies are currently in progress in our laboratory, including means to avoid epitope competition. PASD1 is a model CTA, and this study documents an effective DNA vaccine strategy able to generate CD8 þ CTLs that lyse native human MM cells in a pre-clinical setting. This validation, utilizing the HHD model is both necessary and sufficient to move a specific DNA vaccine into the clinical setting. The anti-PASD1 DNA vaccines are generic, with potential for use not only in MM, but also in other histologically distinct tumors known to express CTAs. The DNA vaccine strategy allows broad usage: it has been designed to overcome tolerance, even in a particularly stringent setting, 6 to counter effects of tumor. The fusion of bacterial 'alert' genes allows recruitment of CD4 þ T-cell help, likely to pre-exist against TT in cancer patients. 25 In a prophylactic setting, the expectation is that these DNA gene fusion vaccines function optimally, as an intact immune system is armed in the absence of tumor-associated tolerising effects and immunosuppression. For MM, such an approach is now being considered. It has been established that this malignancy arises almost invariably from the 'benign' precondition, monoclonal gammopathy of undetermined significance. 26 Remarkably, specific T-cell responses against the embryonal antigen SOX2 in asymptommatic plasma cell tumors correlate strongly with a reduced risk of progression to MM. 27 A number of CTAs are also expressed in monoclonal gammopathy of undetermined significance, 28 and these, together with SOX2 could be potential prophylactic targets during the asymptommatic phase of disease. In the therapeutic setting, the first goal for clinical use of these DNA vaccines was to assess if specific immune responses could be induced. A comparable pre-clinical modeling allowed the use of a DNA vaccine in a clinical trial to target prostate-specific membrane antigen in prostate cancer in our institution, coupled with EP as prime/boost to augment antigen presentation. 25 Most patients revealed anti-DOM antibody responses, improved by EP, as well as CD4 þ T-cells responses. Notably, CD8
þ T-cells were detected against prostate-specific membrane antigen in B60% of cases, at a higher level following EP. 25 The challenge now is to examine whether clinical benefit will result. For this, an extensive trial of a DNA vaccine to target WT1 in chronic myeloid leukemia has been approved, with control arms, and is currently recruiting (lead: Professor Christian Ottensmeier, Cancer Sciences Division, University of Southampton School of Medicine, UK). The primary end point of this randomized trial is control of disease. Clinical efficacy of vaccination in a therapeutic setting is now clearly feasible, as recently demonstrated by the dendritic cellbased vaccine (Provenge) to yield a significant survival advantage in prostate cancer, and leading to FDA approval.
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